Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;76(3):475-83.
doi: 10.1111/bcp.12078.

Reduced indinavir exposure during pregnancy

Tim R Cressey  1 , Brookie M Best, Jullapong Achalapong, Alice Stek, Jiajia Wang, Nantasak Chotivanich, Prapap Yuthavisuthi, Pornnapa Suriyachai, Sinart Prommas, David E Shapiro, D Heather Watts, Elizabeth Smith, Edmund Capparelli, Regis Kreitchmann, Mark Mirochnick; IMPAACT P1026s team
Collaborators, Affiliations

Reduced indinavir exposure during pregnancy

Tim R Cressey et al. Br J Clin Pharmacol. 2013 Sep.

Abstract

Aim: To describe the pharmacokinetics and safety of indinavir boosted with ritonavir (IDV/r) during the second and third trimesters of pregnancy and in the post-partum period.

Methods: IMPAACT P1026s is an on-going, prospective, non-blinded study of antiretroviral pharmacokinetics (PK) in HIV-infected pregnant women with a Thai cohort receiving IDV/r 400/100 mg twice daily during pregnancy through to 6-12 weeks post-partum as part of clinical care. Steady-state PK profiles were performed during the second (optional) and third trimesters and at 6-12 weeks post-partum. PK targets were the estimated 10(th) percentile IDV AUC (12.9 μg ml(-1)h) in non-pregnant historical Thai adults and a trough concentration of 0.1 μg ml(-1), the suggested minimum target.

Results: Twenty-six pregnant women were enrolled; thirteen entered during the second trimester. Median (range) age was 29.8 (18.9-40.8) years and weight 60.5 (50.0-85.0) kg at the third trimester PK visit. The 90% confidence limits for the geometric mean ratio of the indinavir AUC(0,12 h) and Cmax during the second trimester and post-partum (ante : post ratios) were 0.58 (0.49, 0.68) and 0.73 (0.59, 0.91), respectively; third trimester/post-partum AUC(0,12 h) and Cmax ratios were 0.60 (0.53, 0.68) and 0.63 (0.55, 0.72), respectively. IDV/r was well tolerated and 21/26 women had a HIV-1 viral load < 40 copies ml(-1) at delivery. All 26 infants were confirmed HIV negative.

Conclusion: Indinavir exposure during the second and third trimesters was significantly reduced compared with post-partum and ∼30% of women failed to achieve a target trough concentration. Increasing the dose of IDV/r during pregnancy to 600/100 mg twice daily may be preferable to ensure adequate drug concentrations.

Keywords: HIV; antiretrovirals; pregnancy; prevention of mother-to-child transmission.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median (± interquartile range) indinavir concentration vs. time curves for HIV-infected pregnant women using indinavir/ritonavir 400/100 mg twice daily during the second and third trimesters of pregnancy and post-partum. Dashed line represents the typical 50th percentile concentrations in non-pregnant historical Thai adults. formula image, second trimester; formula image, third trimester; formula image, post-partum; formula image, non-pregnant
Figure 2
Figure 2
Individual indinavir (A) AUC(0,12 h) and (B) C12 h for HIV-infected pregnant women using 400/100 mg twice daily during the second and third trimesters of pregnancy and post-partum. Dashed line represents (A) the 10th percentile AUC (12.9 μg ml−1 h) in non-pregnant historical patients and (B) suggested minimum target trough concentration (0.1 μg ml−1)
Figure 3
Figure 3
(A) Maternal delivery and cord blood indinavir concentrations plotted against the interval between maternal dosing and delivery. • maternal plasma indinavir concentration at delivery and ▵ cord blood indinavir concentrations; LLOQ, lower limit of assay quantification. (B) Maternal/cord blood indinavir concentrations ratio plotted against the interval between maternal dosing and delivery
See this image and copyright information in PMC

References

    1. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071–1087. - PubMed
    1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011; pp 1–207. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf (last accessed 5 June 2012)
    1. Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011;56:412–419. - PMC - PubMed
    1. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. Reduced lopinavir exposure during pregnancy. Aids. 2006;20:1931–1939. - PubMed
    1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Jr, Feinberg JE, Balfour HH, Jr, Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725–733. - PubMed

Publication types

MeSH terms